Management Team

Alan Collier

Chairman & Chief Executive Officer

Mr. Collier has more than twenty years of experience in corporate finance, IP development, telecommunications and technology with a concentration in healthcare and technology over the last five years. Prior to his appointment as Endonovo’s CEO and chairman, Mr. Collier served as CEO and director of IP Resources International, Inc. where he was instrumental in developing a platform for the licensing and acquisition of life science and technology companies.

Previously, Mr. Collier served as a Senior Managing Director at Mid-Market Securities, a FINRA-registered Broker-Dealer. Prior to joining Mid-Market Securities, Mr. Collier was a Managing Director at Mosaic capital and co-managed its Capital Markets Group. He was previously a Vice President at Corporate Capital Group and Managing Director and CEO of Greenbridge Capital Group.

Over the progression of his career, he has specialized in the development and financing of early stage, high growth, and acquisitive companies (public and private). He has structured, participated in, and completed numerous transactions including mergers and acquisitions, equity and debt placements, capital restructuring, joint venture development, and channel partner procurement. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Mr. Collier has previously held FINRA Series 7, 79, 63, and 24 Licenses.

Garry Michael Kann

Head of Corporate Development

Mr. Kann, the founding partner of Firebird Partners is a prominent corporate finance professional with over 30 years experience in doing leveraged buyouts and hostile takeovers. During that time he has completed more than 60 merger & acquisition (M&A) transactions exceeding $2 billion in value. Previously, while serving in various senior management positions, he worked with companies in 45 different industry specialties to structure and complete more than 200 business M&A transactions exceeding several billion dollars in value. Mr. Kann received his Bachelor’s degree from Kean University in New Jersey.

Ira Weisberg

President & Chief Commercial Officer of Company’s Medical Division

Mr. Weisberg has more than thirty years of experience in healthcare and pharmaceutical management, business development, corporate finance and marketing with a concentration in pharmaceutical and biotechnology corporate fund-raising strategy over the past five years. His expertise is in developing strategies to guide emerging medical companies to advance revenue and enhance company diversity, developmental pipelines and geographic reach particularly in fast-growing emerging medical device and pharmaceutical markets. Mr. Weisberg has been instrumental in developing licensing and acquisition strategy for an emerging specialty pharmaceutical and medical device biotechnology companies. Prior to his appointment as Endonovo’s President and Chief Commerical Officer of its Medical Division, Mr. Weisberg served as CEO and President of Amherst Pharmaceuticals, CEO of AlphaVax and Senior Vice President of Neurotrope Biosciences where he was responsible for commercial development, corporate funding, strategic planning and overseeing expansion of global operations through acquisition of licensing and partnering agreements for emerging pharmaceuticals, medical devices and other products.

Over his career, Mr. Weisberg has extensive executive experience in healthcare and pharmaceutical management, business development, finance, sales and marketing. Mr. Weisberg led negotiations and signed licensing agreements for strategic acquisitions, distribution and development deals for multiple companies in the medical device and pharmaceutical industry. His past medical administrative experience includes executive positions at Alphavax, Inc., Lifecycle Pharma, Chugai Pharma USA, Haemacure Corp and Aventis Behring. As Senior business development director with Aventis Behring, a global leader in recombinant albumin, he negotiated out-licensing, supply, distribution and development agreements with major pharmaceutical companies in excess of $100 million and contributed to revenues for the company’s specialty product valued at $500 million while assisting the company to be valued in excess of $750 million. As Vice President of Operations for Haemacure Corp., the U.S. market leader in plasma-derived surgical hemostats and adhesives, Mr. Weisberg established and positioned the company globally through negotiations and signing of multinational licensing and joint venture agreements. He guided growth and generated revenue more than $30 million in an IPO, providing capital for growth and product development.

Over the progression of his career, Mr. Weisberg has been recognized as a leading executive who has specialized in the marketing, operations and product development with established pharmaceutical and early-stage biotechnology companies (both public and private). He has structured, participated in and completed numerous transactions including mergers and acquisitions, equity, and joint ventures.

He joins the Endonovo executive team to structure and oversee the global expansion of licensing and distribution for SofPulse® and Roma® PEMF medical device technology.